PURPOSE: The Manchester Foot Pain and Disability Index (MFPDI) is a self-assessment 19-item questionnaire developed in the UK to measure foot pain and disability. This study aimed at conducting cross-cultural adaptation and validation of the MFPDI for use in Spain. METHODS: Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes measures were followed in the MFPDI adaptation into Spanish. The cross-cultural validation involved Rasch analysis of pooled data sets from Spain and the UK. RESULTS: Spanish data set comprised 338 patients, five used in the adaptation phase and 333 in the cross-cultural validation phase, mean age (SD) = 55.2 (16.7) and 248 (74.5 %) were female. A UK data set (n = 682) added in the cross-cultural validation phase; mean age (SD) = 51.6 (15.2 %) and 416 (61.0 %) were female. A preliminary analysis of the 17-item MFPDI revealed significant local dependency of items causing significant deviation from the Rasch model. Grouping all items into testlets and re-analysing the MFPDI as a 3-testlet scale resulted in an adequate fit to the Rasch model, χ (2) (df) = 15.945 (12), p = 0.194, excellent reliability and unidimensionality. Lack of cross-cultural invariance was evident on the functional and personal appearance testlets. Splitting the affected testlets discounted the cross-cultural bias and satisfied requirements of the Rasch model. Subsequently, the MFPDI was calibrated into interval-level scales, fully adjusted to allow parametric analyses and cross-cultural data comparisons when required. CONCLUSIONS: Rasch analysis has confirmed that the MFPDI is a robust 3-subscale measure of foot pain, function and appearance in both its English and Spanish versions.
PURPOSE: The Manchester Foot Pain and Disability Index (MFPDI) is a self-assessment 19-item questionnaire developed in the UK to measure foot pain and disability. This study aimed at conducting cross-cultural adaptation and validation of the MFPDI for use in Spain. METHODS: Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes measures were followed in the MFPDI adaptation into Spanish. The cross-cultural validation involved Rasch analysis of pooled data sets from Spain and the UK. RESULTS: Spanish data set comprised 338 patients, five used in the adaptation phase and 333 in the cross-cultural validation phase, mean age (SD) = 55.2 (16.7) and 248 (74.5 %) were female. A UK data set (n = 682) added in the cross-cultural validation phase; mean age (SD) = 51.6 (15.2 %) and 416 (61.0 %) were female. A preliminary analysis of the 17-item MFPDI revealed significant local dependency of items causing significant deviation from the Rasch model. Grouping all items into testlets and re-analysing the MFPDI as a 3-testlet scale resulted in an adequate fit to the Rasch model, χ (2) (df) = 15.945 (12), p = 0.194, excellent reliability and unidimensionality. Lack of cross-cultural invariance was evident on the functional and personal appearance testlets. Splitting the affected testlets discounted the cross-cultural bias and satisfied requirements of the Rasch model. Subsequently, the MFPDI was calibrated into interval-level scales, fully adjusted to allow parametric analyses and cross-cultural data comparisons when required. CONCLUSIONS: Rasch analysis has confirmed that the MFPDI is a robust 3-subscale measure of foot pain, function and appearance in both its English and Spanish versions.
Authors: Morten Aa Petersen; Mogens Groenvold; Jakob B Bjorner; Neil Aaronson; Thierry Conroy; Ann Cull; Peter Fayers; Marianne Hjermstad; Mirjam Sprangers; Marianne Sullivan Journal: Qual Life Res Date: 2003-06 Impact factor: 4.147
Authors: N W Scott; P M Fayers; N K Aaronson; A Bottomley; A de Graeff; M Groenvold; M Koller; M A Petersen; M A G Sprangers Journal: Qual Life Res Date: 2006-11-16 Impact factor: 4.147
Authors: Andrea Marinozzi; Nicolò Martinelli; Manlio Panascì; Francesco Cancilleri; Edoardo Franceschetti; Bruno Vincenzi; Alberto Di Martino; Vincenzo Denaro Journal: Qual Life Res Date: 2009-07-09 Impact factor: 4.147
Authors: Emmanuel Navarro-Flores; Marta Elena Losa-Iglesias; Ricardo Becerro-de-Bengoa-Vallejo; María Reina-Bueno; Daniel López-López; Carlos Romero-Morales; Patricia Palomo-López; César Calvo-Lobo Journal: Int Wound J Date: 2020-05-27 Impact factor: 3.315
Authors: Tom P Walsh; John B Arnold; Tiffany K Gill; Angela M Evans; Alison Yaxley; Catherine L Hill; E Michael Shanahan Journal: Rheumatol Int Date: 2017-05-17 Impact factor: 2.631
Authors: Emmanuel Navarro-Flores; Carlos Romero-Morales; Jorge Hugo Villafañe; Ricardo Becerro-de-Bengoa-Vallejo; Daniel López-López; Marta Elena Losa-Iglesias; César Calvo-Lobo; Patricia Palomo-López Journal: Int Wound J Date: 2021-05-03 Impact factor: 3.315
Authors: Matylda Sierakowska; Stanisław Sierakowski; Justyna Sierakowska; Mike Horton; Mwidimi Ndosi Journal: Qual Life Res Date: 2014-09-18 Impact factor: 4.147
Authors: Hylton B Menz; Maria Auhl; Sonja Ristevski; Nicoletta Frescos; Shannon E Munteanu Journal: Health Qual Life Outcomes Date: 2014-10-25 Impact factor: 3.186
Authors: Tom P Walsh; Paul A Butterworth; Donna M Urquhart; Flavia M Cicuttini; Karl B Landorf; Anita E Wluka; E Michael Shanahan; Hylton B Menz Journal: J Foot Ankle Res Date: 2017-07-25 Impact factor: 2.303
Authors: María Reina-Bueno; Pedro V Munuera-Martínez; Sergio Pérez-García; María Del Carmen Vázquez-Bautista; Gabriel Domínguez-Maldonado; Inmaculada C Palomo-Toucedo Journal: Int J Environ Res Public Health Date: 2021-05-10 Impact factor: 3.390
Authors: Emmanuel Navarro-Flores; Marta Elena Losa-Iglesias; Ricardo Becerro-de-Bengoa-Vallejo; Daniel Lopez-Lopez; Juan Manuel Vilar-Fernandez; Patricia Palomo-Lopez; Cesar Calvo-Lobo Journal: Aging Dis Date: 2018-10-01 Impact factor: 6.745
Authors: Emmanuel Navarro-Flores; Marta Elena Losa-Iglesias; Ricardo Becerro-de-Bengoa-Vallejo; Daniel López-López; David Rodríguez-Sanz; Patricia Palomo-López; César Calvo-Lobo Journal: Int J Environ Res Public Health Date: 2018-10-10 Impact factor: 3.390